Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network
被引:23
作者:
Sciabola, Simone
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Sciabola, Simone
[2
]
Goetz, Gilles H.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Goetz, Gilles H.
[1
]
Bai, Guoyun
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Bai, Guoyun
[1
]
Rogers, Bruce N.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Rogers, Bruce N.
[2
]
Gray, David L.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Gray, David L.
[2
]
Duplantier, Allen
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Duplantier, Allen
[2
]
Fonseca, Kari R.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Cambridge, MA 02139 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Fonseca, Kari R.
[3
]
Vanase-Frawley, Michelle A.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Vanase-Frawley, Michelle A.
[1
]
Kablaoui, Natasha M.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USAPfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
Kablaoui, Natasha M.
[2
]
机构:
[1] Pfizer Global Res & Dev, Worldwide Med Chem, Groton Labs, Eastern Point Rd, Groton, CT 06340 USA
[2] Pfizer Global Res & Dev, Worldwide Med Chem, Neurosci, 610 Main St, Cambridge, MA 02139 USA
[3] Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Cambridge, MA 02139 USA
Oxytocin (OT) is a peptide hormone agonist of the OT receptor (OTR) that plays an important role in social behaviors such as pair bonding, maternal bonding and trust. The pharmaceutical development of OT as an oral peptide therapeutic has been hindered historically by its unfavorable physicochemical properties, including molecular weight, polarity and number of hydrogen bond donors, which determines poor cell permeability. Here we describe the first systematic study of single and multiple N-methylations of OT and their effect on physicochemical properties as well as potency at the OT receptor. The agonist EC50 and percent effect for OTR are reported and show that most N-methylations are tolerated but with some loss in potency compared to OT. The effect of N-methylation on exposed polarity is assessed through the EPSA chromatographic method and the results validated against NMR temperature coefficient experiments and the determination of NMR solution structures. We found that backbone methylation of residues not involved in IMHB and removal of the N-terminal amine can significantly reduce the exposed polarity of peptides, and yet retain a significant OTR agonist activity. The results of this study also expose the potential challenge of using the N-methylation strategy for the OT system; while exposed polarity is reduced, in some cases backbone methylation produces a significant conformational change that compromises agonist activity. The data presented provides useful insights on the SAR of OT and suggests future design strategies that can be used to develop more permeable OTR agonists based on the OT framework. (C) 2016 Published by Elsevier Ltd.